Navigation Links
Data show drug being tested to reduce cardiovascular events increased risk of heart attack
Date:11/18/2013

Monday, Nov. 18, 2013, Cleveland: Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events including sudden death, heart attack and stroke than those treated with placebo, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

The results of the VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) trial, which was halted last year for futility and possible harm, were presented today at the American Heart Association Scientific Sessions 2013 in Dallas and published simultaneously in the Journal of the American Medical Association (JAMA).

Varespladib inhibits production of the compound secretory phospholipase A2 (sPLA2), which promotes the vascular inflammation implicated in the development of atherosclerosis, or the clogging and hardening of arteries.VISTA-16 was designed to test whether the use of varespladib to reduce sPLA2 would lower the risk of cardiovascular events in patients with acute coronary syndrome. Patients with acute coronary syndrome have had a heart attack or experienced unstable angina, which can lead to a heart attack.

Rather than reduce additional cardiovascular events, including sudden death, heart attack, stroke, and unstable angina, the study found that patients treated with varespladib were more likely than those treated with placebo to experience these events. Both groups of patients were also treated with statin therapy and standard-of-care protocols. The primary endpoint, a composite of sudden death, heart attack, stroke and unstable angina, occurred in 6.1 percent of patients on varespladib compared to 5.1 percent of those on placebo.

In addition, the study found that varespladib was associated with a significantly greater risk of heart attack, occurring in 3.4 percent of the study population on varespladib and 2.2 percent of those on placebo.

After reviewing this data, the trial's independent Data and Safety Monitoring Board called off the trial in March 2012.

"Despite prior experimental and observational data suggesting that varespladib would have beneficial cardiovascular effects, this trial proves the contrary, that it is actually detrimental to cardiovascular morbidity and mortality," said VISTA-16 executive committee chair Stephen J. Nicholls, M.D., Ph.D., senior consultant to Cleveland Clinic's C5Research and Professor of Cardiology and Deputy Director at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia.

"The drug cannot be used to prevent cardiovascular events in patients with acute coronary syndrome," he said.

The researchers do not know whether the outcome of the VISTA-16 trial is attributable to the varespladib molecule itself, or the across-the-board inhibition of sPLA2, which is known to have both protective and inflammatory affects on the cardiovascular system.

"We know that vascular inflammation plays a significant role in the development of coronary disease, and it's important for the scientific community to continue to pursue drugs that may ease the inflammatory process and reduce cardiovascular risk," said Steven Nissen, M.D., senior author on the JAMA paper and Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic. "Unfortunately, the complexity of the inflammatory process continues to confound our efforts at taming it."

VISTA-16 was a double-blind, randomized, placebo-controlled trial designed to enroll more than 5,000 patients at 362 academic and community hospitals in Australia, Europe, India, New Zealand, and North America. It was an academically directed trial developed by an independent executive steering committee with input from the sponsor, Anthera Pharmaceuticals, and monitored by a Data and Safety Monitoring Board independent from both the executive committee and the sponsor.


'/>"/>

Contact: Wyatt DuBois
duboisw@ccf.org
216-445-9946
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Two Easy Tips for Better Well-Being and Enhanced Skin Quality from Sublime Beauty®
2. New statistical tools being developed for mining cancer data
3. Yogafit Partners With Wholebeing Institute, Bringing Positive Psychology Into Yoga Therapy Training
4. Sarah Gentry Presents “Creative Healing and Recovery: The Use of Creative Healing to Foster Emotional Well Being” Workshop
5. DuPont C8 Lawsuits Alleging Kidney Cancer Due to Exposure to C8 Tainted Water From DuPont's Washington Works Plant Being Investigated by Wright & Schulte LLC
6. Body Systems Design Inc. Announces New Well-Being Course through Hippocrates Health Institute Partnership
7. Study compares types of insurance of nursing home residents and likelihood of being hospitalized
8. My Positive Perspective Broadcasts Episode on Event that Benefits the Lowcountry Food Bank and is Being Run in Cooperation with Charleston Parks and Recreation
9. Upgraded Dragon Medical Practice Edition 2 Being Offered by Total Voice Technologies with Special Pricing Incentive
10. New Portable Skin Brush with Travel Pouch a Hit at Sublime Beauty®; Continue to Healthy Skin Like Models and Actresses for Well-Being
11. Fully Dissolvable, Temporary Stent for Opening Heart Artery Blockages Now Being Tested at The Mount Sinai Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The ... national conference convening academic faculty engaged in or interested in palliative care education and ... will be held in North County San Diego on Sept. 28 and 29, ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... official 2017 partnership with The Jensie Gran Fondo of Marin. For the second ... rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... their offering. ... research Dry eye Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are ... are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Feb. 23, 2017 The U.S. Food ... PhenoTest BC Kit, performed on the Pheno System. ... that cause bloodstream infections and provide information about ... to (antibiotic sensitivity). The test also reduces the ... important information, which can guide antibiotic treatment recommendations ...
Breaking Medicine Technology: